Efficacy and safety of SIMPLE regimen in treatment of extranodal NK/T-cell lymphoma
10.3760/cma.j.cn115356-20220713-00204
- VernacularTitle:SIMPLE方案治疗结外NK/T细胞淋巴瘤的效果及安全性
- Author:
Miaoling QIU
1
;
Hua YANG
;
Huijun LI
;
Jing HUANG
;
Mei CHEN
;
Yun MA
;
Xiaojuan AN
;
Jinhui HE
;
Xiaoling QIU
;
Jun WANG
;
Jiacai ZHUO
;
Zhimei ZHU
Author Information
1. 香港大学深圳医院血液科，深圳 518053
- Keywords:
Lymphoma, extranodal NK-T-cell;
Drug therapy, combination;
SIMPLE regimen;
Treatment outcome
- From:
Journal of Leukemia & Lymphoma
2023;32(4):210-214
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of SIMPLE regimen in the treatment of extranodal NK/T-cell lymphoma (ENKTCL).Methods:The clinical data of 11 patients with ENKTCL who were admitted to the University of Hong Kong-Shenzhen Hospital from January 2012 to January 2022 were retrospectively analyzed. The patients received 4-6 courses of SIMPLE (cisplatin, gemcitabine, ifosfamide, etoposide, dexamethasone, and pegasparaginase) regimen chemotherapy, and stage Ⅰ and Ⅱ patients who also received local radiotherapy after 2 or 3 courses of chemotherapy. Patients were evaluated for mid-treatment and end-of-treatment outcomes, and the adverse effects of patients were evaluated in each treatment cycle. The Kaplan-Meier method was used to analyze the progression-free survival (PFS) and overall survival (OS) of the 11 patients.Results:All 11 patients were nasal type, with the median age of 41 years old (26-67 years old), including 5 males and 6 females, 3 relapsed cases and 8 newly treated cases. Of the 10 patients evaluated for efficacy, 9 achieved complete remission and 1 achieved at least partial remission (efficacy was assessed based on follow-up). All 11 patients were followed up for a median time of 50 months (15-72 months) and 2 relapsed patients died due to disease progression. The expected 5-year PFS rate and OS rate of 11 patients were both 90.0%, and the expected 5-year OS rate was 100.0% and 66.6% in newly treated and relapsed patients, respectively. Common adverse effects were hematologic adverse reactions, infections, gastrointestinal symptoms, elevated transaminases, and hypofibrinogenemia, all of which were curable. There is no treatment-related death.Conclusions:The SIMPLE regimen for the treatment of ENKTCL has a high remission rate, the patients have long survival time, and the regimen is moderately well tolerated.
